|
|
| | LORGLUMIDE Basic information |
| Product Name: | LORGLUMIDE | | Synonyms: | 4-dichlorobenzoyl)amino)-5-(dipentylamino)-5-oxo-4-(((+-)-pentanoicaci;cr1409;d,l-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pentanoicacid;LORGLUMIDE;LORGLUMIDE SODIUM SALT (CR 1409) NON-PEP TIDE CCK ANTAG;(±)-4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid sodium salt;CR 1409, (±)-4-[(3,4-Dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid sodium salt;IEKOTSCYBBDIJC-UHFFFAOYSA-N | | CAS: | 97964-56-2 | | MF: | C22H32Cl2N2O4 | | MW: | 459.41 | | EINECS: | | | Product Categories: | | | Mol File: | 97964-56-2.mol |  |
| | LORGLUMIDE Chemical Properties |
| Boiling point | 621.4±55.0 °C(Predicted) | | density | 1.195±0.06 g/cm3(Predicted) | | solubility | 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: >10 mg/mL | | pka | 4.47±0.10(Predicted) | | form | solid | | color | white |
| WGK Germany | 2 | | RTECS | SA3680700 |
| | LORGLUMIDE Usage And Synthesis |
| Uses | Lorglumide is a specific cholecytokinin receptor antagonist. It is also an intermediate in synthesizing Lorglumide Sodium Salt (L469910), a nonpeptidic antagonist of the CCK A receptor, and minimally effective at the CCK B receptor. It blocks CCK -mediated muscle contraction, pancreatic growth and secretion. | | Definition | ChEBI: N(2)-(3,4-dichlorobenzoyl)-N,N-dipentyl-alpha-glutamine is a dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-(3,4-dichlorobenzoyl)glutamic acid with the amino group of dipentylamine. It is a glutamic acid derivative, a dicarboxylic acid monoamide, a member of benzamides and a dichlorobenzene. |
| | LORGLUMIDE Preparation Products And Raw materials |
|